The trial, led by Professor Robert Bals, Director of nan Department of Internal Medicine V astatine Saarland University Medical Center and Professor of Internal Medicine astatine Saarland University, divided nan 450 participants into 2 groups. The curen group of 227 individuals utilized an azelastine nasal spray 3 times a time complete a 56-day period. During that aforesaid period, nan 223 participants successful nan power group utilized a placebo spray 3 times a day. Robert Bals summarized nan cardinal uncovering arsenic follows: 'During nan study period, 2.2% of nan participants successful nan azelastine group became infected pinch SARS-CoV-2; successful nan placebo group, it was 6.7%-three times arsenic many.' All infections were confirmed by PCR testing.
In summation to showing a marked simplification successful coronavirus infections, nan azelastine group besides displayed less symptomatic SARS-CoV-2 infections, a little wide number of confirmed respiratory infections, and, unexpectedly, a reduced incidence of rhinovirus infections, different awesome origin of respiratory illness. In nan curen group, 1.8% developed a rhinovirus infection, compared to 6.3% successful nan placebo group-a proportionality akin to that seen for SARS-CoV-2.
Azelastine nasal spray has been disposable for decades arsenic an over-the-counter curen for hay fever. Previous successful vitro studies connected azelastine had already suggested antiviral effects against SARS-CoV-2 and different respiratory viruses. 'This objective proceedings is nan first to show a protective effect successful a real-world setting,' says Professor Bals.
For Robert Bals, nan results propose applicable applications: 'Azelastine nasal spray could supply an further easy accessible prophylactic to complement existing protective measures, particularly for susceptible groups, during periods of precocious infection rates, aliases earlier travelling.' But Professor Bals besides stressed nan value of further research: 'Our results item nan request for larger, multicentre tests to proceed exploring nan usage of azelastine nasal sprays arsenic an on-demand preventive treatment, and to analyse its imaginable effectiveness against different respiratory pathogens.'
Besides Professor Bals, nan randomized, double-blind phase 2 study 'CONTAIN' besides progressive nan Institute of Clinical Pharmacy (Professor Thorsten Lehr, Dr. Dominik Selzer), nan Institute of Virology (Professor Sigrun Smola), and nan Saarbrücken-based pharmaceutical institution URSAPHARM Arzneimittel GmbH, which sponsored nan study and manufactured nan investigational product. The Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) contributed done nan investigation groups of Professor Smola and Professor Bals. The task serves arsenic an fantabulous illustration of successful collaboration betwixt world research, manufacture partners and nationalist wellness initiatives successful nan Saarland region.
Source:
Journal reference:
Lehr, T., et al. (2025). Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections. JAMA Internal Medicine. doi.org/10.1001/jamainternmed.2025.4283